Please enable JavaScript to continue using this application.

Compare $AGIO vs $MLYS | Chartloom

Compare

$AGIO vs $MLYS

Agios Pharmaceuticals Inc · Mineralys Therapeutics Inc

AGIO

Agios Pharmaceuticals Inc

MLYS

Mineralys Therapeutics Inc

Compare $AGIO vs $MLYS

Comparing Agios Pharmaceuticals Inc and Mineralys Therapeutics Inc

AGIOAgios Pharmaceuticals Inc

MLYSMineralys Therapeutics Inc

AGIOAgios Pharmaceuticals Inc

Market cap

$1.89B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

6.91x

Rev growth (TTM)

140.6%

YTD performance

17.0%

52W performance

-25.3%

FCF yield

-19.3%

MLYSMineralys Therapeutics Inc

Market cap

$2.06B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

30.20x

Rev growth (TTM)

—

YTD performance

-34.6%

52W performance

-37.7%

FCF yield

-16.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AGIO

MLYS

Detailed metrics comparison

AGIO

Agios Pharmaceuticals Inc

MLYS

Mineralys Therapeutics Inc

Market Cap

AGIO$1.89B

MLYS$2.06B

Enterprise Value

AGIO$1.79B

MLYS$2.02B

Price

AGIO$31.81

MLYS$23.37

P/E Ratio

AGION/A

MLYSN/A

P/S Ratio

AGIO19.24x

MLYS0.00x

EV/Sales

AGIO18.22x

MLYS0.00x

EV/EBITDA

AGIO2.84x

MLYS0.00x

P/B Ratio

AGIO1.85x

MLYS3.79x

P/FCF Ratio

AGION/A

MLYSN/A

EV/FCF

AGIO-4.91x

MLYS-5.96x

PEG Ratio

AGION/A

MLYSN/A

Forward P/E (NTM)

AGION/A

MLYSN/A

Forward P/S (NTM)

AGIO6.91x

MLYS30.20x

Revenue (TTM)

AGIO$98M

MLYS$0

Revenue Growth (YoY)

AGIO140.6%

MLYSN/A

Forward Rev Growth

AGIO92.6%

MLYS106.7%

Gross Margin (TTM)

AGIO92.0%

MLYS0.0%

Operating Margin (TTM)

AGIO0.0%

MLYS0.0%

EBITDA Margin (TTM)

AGIO-461.3%

MLYS0.0%

Net Margin (TTM)

AGIO-418.2%

MLYS0.0%

FCF Margin (TTM)

AGIO-371.4%

MLYSN/A

Net Income (TTM)

AGIO$-411M

MLYS$-350M

FCF (TTM)

AGIO$-365M

MLYS$-339M

EPS (TTM)

AGIO-$6.91

MLYS-$4.13

ROE (TTM)

AGIO-3567.0%

MLYS-5797.0%

ROA (TTM)

AGIO-3306.0%

MLYS-5415.0%

ROIC (TTM)

AGIO-3567.0%

MLYS-5571.0%

Cash

AGIO$100M

MLYS$138M

Debt

AGIO$0

MLYS$98M

Net Cash/Debt

AGIO$100M

MLYS$41M

Current Ratio (TTM)

AGIO10.22x

MLYS34.46x

Quick Ratio (TTM)

AGIO9.14x

MLYS34.24x

Debt/Equity (TTM)

AGIO0.00x

MLYS0.18x

Debt/Assets (TTM)

AGIO0.0%

MLYS0.0%

Interest Coverage (TTM)

AGION/A

MLYSN/A

Net Debt/EBITDA (TTM)

AGIO0.00x

MLYS0.00x

Beta

AGIO0.62

MLYS0.64

52W Performance

AGIO-25.3%

MLYS-37.7%

YTD Performance

AGIO17.0%

MLYS-34.6%

% from 52W High

AGIO-30.8%

MLYS-51.0%

% from 52W Low

AGIO43.0%

MLYS8.9%

Asset Turnover (TTM)

AGIO0.08x

MLYS0.00x

FCF Yield (TTM)

AGIO-19.3%

MLYS-16.5%

Earnings Yield (TTM)

AGIO-21.7%

MLYS-17.0%

Dividend Yield (TTM)

AGION/A

MLYSN/A

Rule of 40

AGIO-230.8

MLYS0.0

EV/GP/RG

AGIO0.06

MLYSN/A

Ticker research

View AGIO research View MLYS research

Metric	AGIO Agios Pharmaceuticals Inc	MLYS Mineralys Therapeutics Inc
Market & Valuation
Market Cap	$1.89B	$2.06B
Enterprise Value	$1.79B	$2.02B
Price	$31.81	$23.37
P/E Ratio	N/A	N/A
P/S Ratio	19.24x	0.00x
EV/Sales	18.22x	0.00x
EV/EBITDA	2.84x	0.00x
P/B Ratio	1.85x	3.79x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.91x	-5.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	6.91x	30.20x
Revenue & Growth
Revenue (TTM)	$98M	$0
Revenue Growth (YoY)	140.6%	N/A
Forward Rev Growth	92.6%	106.7%
Profitability
Gross Margin (TTM)	92.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-461.3%	0.0%
Net Margin (TTM)	-418.2%	0.0%
FCF Margin (TTM)	-371.4%	N/A
Net Income (TTM)	$-411M	$-350M
FCF (TTM)	$-365M	$-339M
EPS (TTM)	-$6.91	-$4.13
ROE (TTM)	-3567.0%	-5797.0%
ROA (TTM)	-3306.0%	-5415.0%
ROIC (TTM)	-3567.0%	-5571.0%
Financial Health
Cash	$100M	$138M
Debt	$0	$98M
Net Cash/Debt	$100M	$41M
Current Ratio (TTM)	10.22x	34.46x
Quick Ratio (TTM)	9.14x	34.24x
Debt/Equity (TTM)	0.00x	0.18x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.62	0.64
52W Performance	-25.3%	-37.7%
YTD Performance	17.0%	-34.6%
% from 52W High	-30.8%	-51.0%
% from 52W Low	43.0%	8.9%
Efficiency & Yields
Asset Turnover (TTM)	0.08x	0.00x
FCF Yield (TTM)	-19.3%	-16.5%
Earnings Yield (TTM)	-21.7%	-17.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-230.8	0.0
EV/GP/RG	0.06	N/A
Ticker research	View AGIO research	View MLYS research

Valuation

P/S Ratio

MLYS

0.00x

AGIO

19.24x

EV/FCF

MLYS

-5.96x

AGIO

-4.91x

Growth & revenue

Revenue Growth TTM

AGIO

140.6%

Forward Revenue Growth

MLYS

106.7%

AGIO

92.6%

Profitability & performance

Gross Margin

AGIO

92.0%

MLYS

0.0%

ROE

AGIO

-3567.0%

MLYS

-5797.0%

FCF Yield %

MLYS

-16.5%

AGIO

-19.3%

52-Week Performance

AGIO

-25.3%

MLYS

-37.7%

Detailed metrics comparison

AGIO

Agios Pharmaceuticals Inc

MLYS

Mineralys Therapeutics Inc

Market Cap

AGIO$1.89B

MLYS$2.06B

Enterprise Value

AGIO$1.79B

MLYS$2.02B

Price

AGIO$31.81

MLYS$23.37

P/E Ratio

AGION/A

MLYSN/A

P/S Ratio

AGIO19.24x

MLYS0.00x

EV/Sales

AGIO18.22x

MLYS0.00x

EV/EBITDA

AGIO2.84x

MLYS0.00x

P/B Ratio

AGIO1.85x

MLYS3.79x

P/FCF Ratio

AGION/A

MLYSN/A

EV/FCF

AGIO-4.91x

MLYS-5.96x

PEG Ratio

AGION/A

MLYSN/A

Forward P/E (NTM)

AGION/A

MLYSN/A

Forward P/S (NTM)

AGIO6.91x

MLYS30.20x

Revenue (TTM)

AGIO$98M

MLYS$0

Revenue Growth (YoY)

AGIO140.6%

MLYSN/A

Forward Rev Growth

AGIO92.6%

MLYS106.7%

Gross Margin (TTM)

AGIO92.0%

MLYS0.0%

Operating Margin (TTM)

AGIO0.0%

MLYS0.0%

EBITDA Margin (TTM)

AGIO-461.3%

MLYS0.0%

Net Margin (TTM)

AGIO-418.2%

MLYS0.0%

FCF Margin (TTM)

AGIO-371.4%

MLYSN/A

Net Income (TTM)

AGIO$-411M

MLYS$-350M

FCF (TTM)

AGIO$-365M

MLYS$-339M

EPS (TTM)

AGIO-$6.91

MLYS-$4.13

ROE (TTM)

AGIO-3567.0%

MLYS-5797.0%

ROA (TTM)

AGIO-3306.0%

MLYS-5415.0%

ROIC (TTM)

AGIO-3567.0%

MLYS-5571.0%

Cash

AGIO$100M

MLYS$138M

Debt

AGIO$0

MLYS$98M

Net Cash/Debt

AGIO$100M

MLYS$41M

Current Ratio (TTM)

AGIO10.22x

MLYS34.46x

Quick Ratio (TTM)

AGIO9.14x

MLYS34.24x

Debt/Equity (TTM)

AGIO0.00x

MLYS0.18x

Debt/Assets (TTM)

AGIO0.0%

MLYS0.0%

Interest Coverage (TTM)

AGION/A

MLYSN/A

Net Debt/EBITDA (TTM)

AGIO0.00x

MLYS0.00x

Beta

AGIO0.62

MLYS0.64

52W Performance

AGIO-25.3%

MLYS-37.7%

YTD Performance

AGIO17.0%

MLYS-34.6%

% from 52W High

AGIO-30.8%

MLYS-51.0%

% from 52W Low

AGIO43.0%

MLYS8.9%

Asset Turnover (TTM)

AGIO0.08x

MLYS0.00x

FCF Yield (TTM)

AGIO-19.3%

MLYS-16.5%

Earnings Yield (TTM)

AGIO-21.7%

MLYS-17.0%

Dividend Yield (TTM)

AGION/A

MLYSN/A

Rule of 40

AGIO-230.8

MLYS0.0

EV/GP/RG

AGIO0.06

MLYSN/A

Ticker research

View AGIO research View MLYS research

Metric	AGIO Agios Pharmaceuticals Inc	MLYS Mineralys Therapeutics Inc
Market & Valuation
Market Cap	$1.89B	$2.06B
Enterprise Value	$1.79B	$2.02B
Price	$31.81	$23.37
P/E Ratio	N/A	N/A
P/S Ratio	19.24x	0.00x
EV/Sales	18.22x	0.00x
EV/EBITDA	2.84x	0.00x
P/B Ratio	1.85x	3.79x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.91x	-5.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	6.91x	30.20x
Revenue & Growth
Revenue (TTM)	$98M	$0
Revenue Growth (YoY)	140.6%	N/A
Forward Rev Growth	92.6%	106.7%
Profitability
Gross Margin (TTM)	92.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-461.3%	0.0%
Net Margin (TTM)	-418.2%	0.0%
FCF Margin (TTM)	-371.4%	N/A
Net Income (TTM)	$-411M	$-350M
FCF (TTM)	$-365M	$-339M
EPS (TTM)	-$6.91	-$4.13
ROE (TTM)	-3567.0%	-5797.0%
ROA (TTM)	-3306.0%	-5415.0%
ROIC (TTM)	-3567.0%	-5571.0%
Financial Health
Cash	$100M	$138M
Debt	$0	$98M
Net Cash/Debt	$100M	$41M
Current Ratio (TTM)	10.22x	34.46x
Quick Ratio (TTM)	9.14x	34.24x
Debt/Equity (TTM)	0.00x	0.18x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.62	0.64
52W Performance	-25.3%	-37.7%
YTD Performance	17.0%	-34.6%
% from 52W High	-30.8%	-51.0%
% from 52W Low	43.0%	8.9%
Efficiency & Yields
Asset Turnover (TTM)	0.08x	0.00x
FCF Yield (TTM)	-19.3%	-16.5%
Earnings Yield (TTM)	-21.7%	-17.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-230.8	0.0
EV/GP/RG	0.06	N/A
Ticker research	View AGIO research	View MLYS research